Do you want to read an article? Please log in or register.
First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis
Lung Cancer
RECOMMENDED
Related content
RECOMMENDED
Lung Cancer
Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Horiuchi K, Sato T, Kuno T, Takagi H, Hirsch FR, Powell CA, Fukunaga K
doi: 10.1016/j.lungcan.2021.04.013
RECOMMENDED
Lung Cancer
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
N Engl J Med.
Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S
doi: 10.1056/NEJMoa1810171.
RECOMMENDED
Lung Cancer
PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
García Campelo MR, Arriola E, Campos Balea B, López-Brea M, Fuentes-Pradera J, de Castro Carpeno J, Aguado C, Pérez Parente D, de Oro Pulido F, Ruiz-Gracia P, Rodríguez-Abreu D
doi: 10.3390/jcm10194583
RECOMMENDED
Lung Cancer
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data
Lung Cancer.
Dall'Olio FG, Maggio I, Massucci M, Mollica V, Fragomeno B, Ardizzoni A
doi: 10.1016/j.lungcan.2020.04.027.
RECOMMENDED
COPD
Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis
Cochrane Database Syst Rev.
Oba Y, Keeney E, Ghatehorde N, Dias S
doi: 10.1002/14651858.
RECOMMENDED
Lung Cancer
Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR+ and ALK+ Positive Non-small-cell Lung Cancer Treated in the Real-World
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Goulart BHL, Chennupati S, Fedorenko CR, Ramsey SD
doi: 10.1016/j.cllc.2021.01.019
RECOMMENDED
Lung Cancer
Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies
Clin Lung Cancer.
Schulz C, Gandara D, Berardo CG, Rosenthal R, Foo J, Morel C, Ballinger M, Watkins C,
Chu P
doi: 10.1016/j.cllc.
RECOMMENDED
Lung Cancer
Racial Differences in Adherence to Lung Cancer Screening Follow-Up: A Systematic Review and Meta-Analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Chest
Kunitomo Y, Bade B, Gunderson CG, Akgün KM, Brackett A, Cain H, Tanoue L, Bastian LA
doi: 10.1016/j.chest.2021.07.2172
RECOMMENDED
Lung Cancer
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
N Engl J Med.
Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S
doi: 10.1056/NEJMoa1810171.